


Cranberry


- Vaccinium macrocarpon-cultivated in Washington
 - •Long history of use

- •The mechanism was thought to be urine acidification
- Now E. coli (other pathogens also) adhesion inhibitors are known to be present but not in other juices. An unidentified, high mol wt material may be responsible
- Need about 8-16 oz (240-480ml) of juice (not drink or cocktail)
 - •Mu¢h less evidence for efficacy of cranberry capsules

■ Evidence for effectiveness in UTI **treatment** is weak

- Will acidify urine and contains high oxalic acid levels so that kidney stones could be a risk
- Cranberry juice will also reduce urine pH and ammonia odor.
- One study showed enhanced eradication of H. pylori when added to an antibiotic regimen.





Kontiokari et al. BMJ 2001;322:1571 n=150 50ml (7.5g) of cranberry concentrate (diluted)(also had some logenberry juice)

Cranberry

■ Summary

- **◆** Efficacy: reasonable evidence for benefit for PREVENTION of UTI.
- ◆ Safety: good but could be risky for those that form kidney stones easily. Has salicylates.
- ◆ Drug interactions: little effect on CYP or warfarin INR
- ◆ Product selection: need the juice; capsules work?
- **◆** Questions remaining include
 - ◆ Does cranberry juice help with Helicobacter pylori?
 - ♦ Other infections?
 - ◆ Help in dental caries?



Soy-


- Botany-Glycine max-legume
- ◆ contains isoflavones that act as estrogen mimics (phytoestrogens), e.g genistein, daidzein, that bind to estrogen receptors in a competitive manner

UGA1320087

- ◆ Isoflavones are present in many plants but soy beans; soy milk and tofu are especially rich sources
- other sources (mainly legumes):fennel seeds, red clover, yam, black beans, licorice
- ♦ 1 cup of soybeans=about 300mg of isoflavones
- ♦ consumption in Japan is ~50mg/d isoflavones

Soy

- also contains lignans
 - are phenylpropanoid dimers with antioxidant and free radical scavanging properties
 - present in many plants but especially soy beans and flaxseed and red clover
 - ◆ Some evidence that ingestion of lignans may decrease risk of some cancers (breast)
 - act like phytoestrogens



Gum, mp 141-143°. uv max (ethanol): 227, 261 nm ($\log \epsilon$ 4.66, 4.64).

Enterolactone (example of a lignan)

Isoflavone Pharmacology

- ☐ •Isoflavones (IF) act a weak estrogenic compounds. Are essentially ☐ SERMs
- □ •IF are competitive inhibitors of estrogen. If estrogen is high □ (premenopause), then will displace; if low (postmenopause) then will □ be an estrogen agonist.
- □ •Bind to estrogen receptor B (bone,vascular) better than ER-A □ (reproductive)
- Have effects other than receptor action. Decrease aromatase, 3 B and 17 B-hydroxysteroid dehydrogenase, enzymes that convert precursor steroids to potent estradiol.
- ☐ •Are antioxidants

- ☐ •Japanese consume 30-40mg isoflavones/d; USA consumes little.
- □ •Japanese women have lower breast cancer and menopause problems

Isoflavones (continued)	
□ Product	mg isoflavones/100g
Raw soybeans	~100
Soy protein	100-300
Soy milk	10
Soy flour	199
Cooked soybeans	55
☐ Tempeh	44
□ Tofu	31
Soy noodles	9

Soy Effects on Cancers


- •Long consumption of soy associated with lower rates of breast, endometrial and prostate cancers (Asian cultures).
- •Animal studies show that high soy protein in diets will reduce incidence and development of several cancers
- •Breast cancer


- •No long term prospective studies
- •In vitro, genistein and daidzein <u>stimulate</u> breast cancer growth in low conc but inhibit at high conc.
- •In mice, genistein increased growth rate of estrogen dependant and estrogen independent <u>implanted</u> tumors and antogonizes tamoxifen but at high concentrations the reverse was true.
- •In mice, genistein or soy given prior to the cancer will protect


Soy Effects on Heart Disease Risks


- •Soy diets associated with normalization of lipid profiles
 - •Decreased total cholesterol (~9%), LDL (~13% decrease), increased HDL(small), triglycerides (~10% decrease) improved artierial dilation and compliance
- •Soy modestly lowers BP

- •In animal studies, soy without isoflavones did not affect lipids
- •FDA now allows foods with 6.25g of soy protein per serving to state "consuming 25g of soy protein daily, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease"
- •May need 20-50g/day of soy in diet for benefit; intake is low in Western countries and not correlated with cardio risk
- •Isoflavones alone may not work









Soy and Menopausal and Postmenopausal problems

•can soy replace HRT?

- •Hot flashes and other symptoms: soy flour as well as higher doses of soy isoflavones (100mg/d) have been tested. The results are generally positive for mild benefit. A big placebo effect is seen in the published studies.
- •Osteoporosis- some studies using high isoflavone soy indicate decreased loss of bone mass in postmenopausal women






Table 2. Data for Fracture by Quintile of Soy Protein Intake

Copyright restrictions may apply

	Quintile of Soy Protein Intake, g/d					
Variable	<4.98 (n = 4880)	4.98-7.32 (n = 4882)	7.33-9.77 (n = 4880)	9.78-13.26 (n = 4880)	≥13.27 (n = 4881)	P Value for Trend
No. of follow-ups	9559	9610	9649	9662	9616	NA
Person-years	21 635	22 091	22 232	22 234	22 052	NA
No. of cases RR (95% CI)	459	332	329	317	333	NA
Age and calorie (energy) adjusted	1.00	0.69 (0.60-0.80)	0.67 (0.58-0.77)	0.63 (0.54-0.73)	0.63 (0.54-0.74)	<.001
Multivariate*	1.00	0.72 (0.62-0.83)	0.69 (0.59-0.80)	0.64 (0.55-0.76)	0.63 (0.53-0.76)	<.001

Abbreviations: CI, confidence interval; NA, data not applicable; RR, relative risk.

*Adjusted for age, body mass index, hours of exercise per week, cigarette smoking, alcohol consumption, history of diabetes mellitus, level of education, family income, season of recruitment, and intakes of total calories, calcium, nonsoy protein, fruits, and vegetables.

Zhang, X. et al. Arch Intern Med 2005;165:1890-1895.

ARCHIVES OF INTERNAL MEDICINE

Data for Fracture by Quintile of Soy Isoflavone Intake

Table 3. Data for Fracture by Quintile of Soy Isoflavone Intake

	Quintile of Soy Isoflavone Intake, mg/d					
Variable	<21.16 (n = 4881)	21.16-32.39 (n = 4881)	32.40-44.31 (n = 4880)	44.32-60.26 (n = 4880)	≥60.27 (n = 4881)	P Value for Trend
No. of follow-ups	9564	9624	9648	9658	9602	NA
Person-years	21654	22 147	22 288	22 136	22 018	NA
No. of cases RR (95% CI)	450	340	312	340	328	NA
Age and calorie (energy) adjusted	1.00	0.72 (0.63-0.83)	0.65 (0.56-0.75)	0.70 (0.60-0.81)	0.65 (0.56-0.76)	<.001
Multivariate*	1.00	0.75 (0.65-0.87)	0.67 (0.58-0.78)	0.72 (0.61-0.84)	0.65 (0.55-0.78)	<.001

Abbreviations: See Table 2

 Zhang, X. et al. Arch Intern Med 2005;165:1890-1895.


Copyright restrictions may apply


ARCHIVES OF INTERNAL MEDICINE

N=88, 24 weeks of soy or whey protein; x=soy containing 80mg/d isoflavones, open square=soy containing 4.4mg/d isoflavones or diamond=whey

Alekel et al. Am J Clin Nutr 2000;72:844-852.

Measurements on lumbar spine






^{*}Adjusted for age, body mass index, hours of exercise per week, cigarette smoking, alcohol consumption, history of diabetes mellitus, level of education, family income, season of recruitment, and intakes of total calories, calcium, nonsoy protein, fruits, and vegetables.

Risks and Interactions

•Can be allergenic for some

- •Soy isoflavones can inhibit thyroid synthesis
- •Soy use in breast cancer patients
 - •Dietary soy may be OK but probably best to avoid supplements (see earlier slide).
 - •Studies generally show no benefit of soy vs placebo in hot flashes associated with breast cancer therapy with tamoxifen (e.g., Van Patten et al. J Clin Oncol 2002;20:1449-1455).
- •Drug Interactions- not to be given with tamoxifen; isoflavones inhibit CYP in vitro but probably not in vivo



Other Effects of Soy

- Diabetes- may improve glucose tolerance
- Diabetes- may improve neuropathy and kidney function
- Memory may see improvement
- Men-prostate- may be slightly protective but no effect on PSA
- Women-may improve immune function

Other herbals used for menopausal symptoms ☐ Red clover- contains lignans and isoflavones; some studies show benefit for menopausal symptom relief, others no benefit ☐ Black cohosh- does not affect endometrium but may relieve hot □ flushes and other menopausal symptoms; may build bone; may not be contraindicated in breast cancer and treatment regimens. More later Flaxseed and Flaxseed oil – some evidence for benefit **Evening primrose oil- not consistent evidence for benefit** ☐ Chasteberry- helps in PMS but ? for menopause Dong quai- no observed benefit in one good study ☐ Yam- is a scam Topical progesterone- works but risks same as HRT?

Soy

- **■** Summary
 - ◆ Efficacy: increased soy ingestion may or may not decrease hot flashes and other postmenopausal symptoms; Soy has cardiovascular benefits.
 - ◆ Safety: good but use in breast cancer may be risky; for infants is OK but low in vitamins
 - ◆ Drug interactions: not with tamoxifen
 - ◆ Product selection: Soy is best. Isoflavones?
 - **◆** Dose: about 20-40g of soy protein has been used. This contains 30-50mg of isoflavones.
 - **◆** Questions remaining include
 - ♦ How much benefit? Safety in breast cancer?









Botany

- •Panax ginseng (Korean or Asian ginseng),
- •Panax quinquefolius (American ginseng)
- •note: Siberian ginseng is different (Eleutherococcus senticosus)
- •steamed and dried product is "red" ginseng vs "white" ginseng which is dried only
- History
- Chemistry-ginsenosides, a series of steroid glycosides. The ratio of these differ between Panax sp.





☐Predy €	et al. CMAJ
2005;1	73:1043-1048
□Note: s	pecial extract of
∐ginseng	g used that contains
□polyfur	anosyl-pyranosyl-
	rides. Product
\square (Cold-I	FX) available in
□Canada	and USA. An
⊏earlier,	smaller study
showed	d activity in
⊟preven	ting flu in older
adults ((McElhaney et al.
$\Box Am \ Ge$	riatrSoc.
2004;5	2:13-19.)
	•

	Group	; no. (%)†		
Outcome	Placebo n = 149	Ginseng extract n = 130	Difference (95% CI)	
Jackson+ colds‡				
No. per person, mean (SD)	0.93 (0.91)	0.68 (0.82)	0.25 (0.04 to 0.45)	
1 cold	95 (63.8)	71 (54.6)	9.1 (-2.4 to 20.7)	
≥ 2 colds	34 (22.8)	13 (10.0)	12.8 (4.3 to 21.3)	
Colds§				
No. per person, mean (SD)	0.99 (1.00)	0.71 (0.83)	0.29 (0.07 to 0.50)	
1 cold	96 (64.4)	73 (56.2)	8.3 (-3.2 to 19.8)	
≥ 2 colds	37 (24.8)	13 (10.0)	14.8 (6.2 to 23.5)	

Table 2: Number of colds over the 4-month intervention period*

Note: SD = standard deviation, CI = confidence interval.

TSubjects providing baseline data only (placebo n = 21, ginseng extract n = 23) were excluded from the data analysis.

\$Total symptom score over 2 days > 14. \$Daily total symptom score > 4.

Table 3: Severity, number of days of symptoms and duration of all colds* over the 4-month intervention period per subject reporting cold symptoms

	Group; mean (SD)				
Outcome	Plac	ebo 96		g extract = 73	Difference† (95% CI)
Total symptom score	112.3	(102.5)	77.5	(84.6)	1.5 (1.2-2.0)
Total symptom score per cold	75.9	(68.3)	64.2	(75.1)	1.3 (1.1-1.6)
Total days with cold symptoms, no.	16.5	(13.8)	10.8	(9.7)	1.6 (1.3-2.0)
Duration of each cold, d	11.1	(8.1)	8.7	(7.2)	1.3 (1.0-1.7)

Note: SD = standard deviation. Cl = confidence interval.


Totally total symptom score > 4.

TStatistical analyses were performed on the log-transformed data; differences and confidence intervals were obtained by transforming back to the original scale using antilogs.



□ •Dose

- 1-2g/d of dried root
- 200mg/d of a standardized extract of the root containing 4-7% ginsenosides; it is recommended to take for 4 weeks then stop for 1-2 weeks.
- Adverse Effects
 - •much listed but close evaluation indicates wide safety; reports of problems may be associated with poor products and adulterated products
- Drug Interactions
 may be CYP i
 - may be CYP inducer (more later)



Ginseng

Efficacy: huge literature of small, uncontrolled studies; some evidence for applications in geriatric patients (improved "quality of life") and in diabetes and common cold (Cold-FX)

Safety: good; reported problems may be due to poor quality product

Drug interactions: may precipitate hypoglycemia with insulin or oral hypoglycemics

Product selection: product should be standardized to deliver about 25mg/dose ginsenosides or about 50mg/d

Dose: 200mg per day of extract

Questions remaining include:

♦ What, actually is this stuff good for!








Black Cohosh

■ Botany

- ◆ Cimicifuga racemosa. A tall perennial shrub in NE USA; roots and rhizomes used
- History
 - ◆ Used by Native Americans for women's health problems and a variety of other uses; A component of Lydia Pinkham's elixir,
 - ◆ In Europe a special black cohosh extract has been used since the 1950s for symptoms of menopause and PMS
- Chemistry
 - ◆ Contains phytosterin, salicylic acid, tannins, and triterpine glycosides that may be important for activity
 - ◆ The triterpine glycosides include acetin, 27-deoxyacetin, and cimicifugoside








- •black cohosh seems to lack estrogen activity in vivo; no effect on uterus (Liske et al. J Women's Health and Gender Based Med. 2002;11:163-174); SERM; mild stimulation of estrogen receptors B.
- •May have central CNS effect on serotonin receptor
- •Does not seem to stimulate estrogen receptor dependant tumors in animals or in vitro tumor cell growth. Humans?


Uses


- •reduce symptoms associated with menopause
- •relieve symptoms of menopause associated with tamoxifen therapy
- •PMS
- •dysmenorrhea
- •hasten childbirthing


Evidence for relief of menopausal symptoms


- •Early studies with Remifemin show support for reducing hot flashes, etc in menopause
- •well designed recent studies indicate benefit and SERM-like activity

















Table 4					
Hot flushes	reduction	by	CR	BNO	1055

Hot flushes	Usual-care group ^a $(n = 46)$	Intervention group ^b $(n = 90)$
Severe	34 (73.9%)	22 (24.4%)
Moderate	12 (26.1%)	26 (28.9%)
None	_	42 (46.7%)

^a Tamoxifen adjuvant therapy.

Munoz and Pluchino Maturitas 2003;44:S59-S65. N=136; 12 mos

^b Combined therapy: tamoxifen+CR BNO 1055.

Safety	
•GI	upset, headache, dizziness possible
du preg	e to possible estrogenic effects, use with caution gnancy
	vitro does not stimulate breast cancer cells (in contrast oy isoflavones) but in vivo the risk is uncertain.
= = •sev	eral reports of severe liver toxicity (causal?)
Produ	icts
use	mifemin (SK Beecham) is a good product that has been d successfully in controlled trials; it is standardized to tain 1mg of 27-deoxyacetin per 20mg tablet.
□ •1 I	BID

Black Cohosh


■ | Summary


- ◆ Efficacy: reasonable evidence for benefit for relief of menopausal symptoms. Mixed evidence for relief of tamoxifen adverse effects.
- ◆ Safety: good but a few case reports of liver toxicity. Safety in women with existing breast cancer is uncertain.
- **◆ Drug interactions: weak 2D6 induction?**
- ◆ Product selection: standardized root extract; 20mg BID; Remifemin is the best tested.
- **◆** Questions remaining include
 - ♦ What is the risk in breast cancer?
 - ♦ What is the risk for hepatotoxicity?


- **Botany**
 - ♦ Hypericum perforatum grows here on campus*
- **■** History
- **Chemistry**
 - ♦ Hypericin
 - ♦ hyperforin











St. John's Wort Pharmacology


- ♦ hypericin

- antiviral acitivity
- ♦ MAOI ? 1984 study found activity but 3 more recent studies say no
- ♦ hyperforin more important
- ◆ Flavonoids
 - ♦ antioxidant
 - ♦ MAOI ? But maybe not in vivo
- ♦ Other? MAOI, SSRI


- Evidence -Depression
 - widely prescribed in Europe for depression
 - ◆ Commission E "approved" for this use
 - Commission E- psychological disturbances, depression, anxiety,nervous unrest; topically the oil for bruises,myalgi, burns


St. John's Wort


- Meta -analysis of 40 randomized trials (Linde et al. Br J Psychiatry. 2005;186:99-107)
 - ◆ 26 trials =double blind, placebo controlled;
 3320 patients
 - ◆ 14 trials = double blind, compared to standard treatment; 2283 patients




	Study	Hypericum n/N	Standard antidepressant n/N	RR (fixed) 95% CI	RR (fixed) 95% C
hintry	Older antidepressants	7.0			
chiatry.	Bergmann 1993	32/40	28/40		1.14 (0.89-1.48)
_	Harrer 1993	27/51	28/51	-	0.96 (0.67-1.38)
	Phillipp 1999	76/106	70/110		1.13 (0.94-1.36)
	Vorbach 1994	42/67	37/68		1.15 (0.87-1.53)
:99-	Vorbach 1997	36/107	41/102		0.84 (0.59-1.20)
• , ,	Wheatley 1997	40/87	42/78		0.85 (0.63-1.16)
	Woelk 2000	68/157	67/167		1.08 (0.83-1.40)
	Subtotal (95% CI)	615	616		1.03 (0.93-1.14)
	Total events: 321 (Hyperic	um), 313 (standard)		7	2010 1000 1000
		=5.14, d.f.=6 (P=0.53) 12=09	5		
	Test for overall effect: Z=				
	Selective serotonin reuptake		21.05		0.74 (0.40 1.00
	Behnke 2002	16/35	21/35		0.76 (0.49-1.20)
	Brenner 2000	7/15	6/15	•	- 1.17 (0.51-2.66
	HDTSG 2002	46/113	55/111		0.82 (0.61-1.10
	Harrer 1999	50/77	57/84	+	0.96 (0.77-1.19
	Schrader 2000	57/125	39/114		1.33 (0.97-1.83)
	van Gurp 2002	20/45	22/45	-	0.91 (0.58-1.42)
	Subtotal (95% CI)	410	404		0.98 (0.85-1.12)
	Total events: 196 (Hyperic				
		=6.49, d.f.=5 (P=0.26), P=2	3.0%		
	Test for overall effect: Z=	0.33 (P=0.74)			
				1	
	Total (95% CI)	1025	1020		1.01 (0.93-1.10)
	Total events: 517 (Hyperic	um), 513 (standard)			
		=12.53, d.f.=12 (P=0.40), 12	4.2%		
	Test for overall effect: Z=				
		1 10 7			
			0.1 0.2	0.5 1 2	5 10
			favours pla	cebo favour	s Hypericum























- Other Uses: less well documented
 - ◆ Seasonal Affective Disorders
 - ♦ n=20 SAD patients
 - ◆ same decrease in Hamilton depression scale with SJW ± light
 - Hypericin antiviral studies
 - hypericin activity against glioma cells
 - SJW long used to heal wounds
 - plant oil has antimicrobial activity

adverse

- photosensitivity-animals
- photosensitivity- humans- in high doses is a risk
 - ♦ 1800mg/d + UVA; not at usual doses
- **♦** SSRI drugs contraindicated. Additive effects with imipramine
- ◆ Open study of 3250, Wolk et al 1994
 - ♦ 0.5% allergic rxns, 0.6% GI, 0.4% fatigue
- **♦ SJW** is a CYP inducer with herbal/drug interactions documented.
- ◆ SJW is a PGP inducer with documented interactions

St. John's Wort

- **■** Summary
 - **◆** Efficacy: good evidence in mild to moderate depression
 - ◆ Safety: don't combine with other medications unless under close monitoring; possible photosensitivity
 - ◆ Drug interactions: a problem. Is a P450 inducer and a p-glycoprotein inducer
 - ◆ Product selection: want standardized extract containing about 0.3% hypericin or 2-3% hyperforin; 300mg TID for treatment; LI160 and WS1172 extracts are the best studied
 - **◆** Questions remaining include
 - ◆ How best to use this herbal given that there are drug interaction problems

3 5 2 1, 3 - 3	hn's Wort Los Reyes and Koda, Am J Health-syst Pharm 59:545-547.2002				
	•				
◆ Product-	hypericin (%) hyperf	<u> </u>			
■ Hyperifin	0.29	1.89			
■ PNC	0.12	0.20			
■ Brite-Life	0.22	1.16			
■ ShopKo	0.26	0.05			
■ Shurfine	0.17	0.29			
■ YourLife	0.28	0.19			
■ Nature's Balance	0.03	0.01			
■ Natrol	0.25	0.48			

^{*} Usually want 0.3% hypericin and 1-2% hyperforin